COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity

Erra, L; Uriarte, I; Colado, A; Paolini, MV; Seminario, G; Fernández, JB; Tau, L; Bernatowiez, J; Moreira, I; Vishnopolska, S; Rumbo, M; Cassarino, C; Vijoditz, G; López, AL; Curciarello, R; Rodríguez, D; Rizzo, G; Ferreyra, M; Mufarregue, LRF; Badano, MN; Millán, MIP; Quiroga, MF; Baré, P; Ibañez, I; Pozner, R; Borge, M; Docena, G; Bezrodnik, L; Almejun, MB

Almejun, MB (通讯作者),Consejo Nacl Invest Cient & Tecn, Dept Fisiol Biol Mol & Celular, Inst Biociencias Biotecnol & Biol Traslac IB3, Buenos Aires, Caba, Argentina.;Almejun, MB (通讯作者),Consejo Nacl Invest Cient & Tecn, Inst Quim Biol IQUIBICEN, FCEN, UBA, Buenos Aires, Caba, Argentina.;Almejun, MB (通讯作者),Univ Buenos Aires, Fac Ciencias Exactas & Nat, Pabellon 2,Intendente Giliraldes 2160, Buenos Aires, DF, Argentina.

JOURNAL OF CLINICAL IMMUNOLOGY, 2023; 43 (2): 271

Abstract

Patients with inborn errors of immunity (IEI) in Argentina were encouraged to receive licensed Sputnik, AstraZeneca, Sinopharm, Moderna, and Pfizer va......

Full Text Link